Skip to content

HHRI Media Coverage

HHRI Media Coverage

2022

November

During the COVID-19 pandemic, transplantation of COVID-19 infected deceased donor kidneys gradually increased from 2020 to 2021 in the United States, before spiking in the first quarter of 2022, investigators revealed at Kidney Week 2022, the annual meeting of the American Society of Nephrology, in Orlando, Florida. Recipients of COVID-19 positive donor kidneys had no worse graft outcomes than other recipients. A total of 1731 (67.7%) COVID-19 positive kidneys were transplanted, 714 (27.9%) were recovered but not transplanted, and 108 (4.2%) were not recovered at all, Warren McKinney, PhD, of Hennepin Healthcare Research Institute, University of Minnesota in Minneapolis reported on behalf of his team. Yet the risks for all-cause graft failure and death did not differ significantly between recipients of COVID-19 positive vs negative donor kidneys, he stated. Cold ischemia times were longer for COVID-19 positive kidneys, however. The team did not examine rates of delayed graft function. He told Renal & Urology News that “high discard rates for COVID-positive donors and greater cold ischemic times may suggest that such donor kidneys remain difficult to place. Patient- and transplant program-level interventions targeting decision support and risk aversion may be necessary to reduce discard rates for COVID-positive donor kidneys.” Co-investigator and Hennepin Healthcare Research Institute President, Ajay Israni, MD, MS, added: “Nephrologists should assure transplant candidates that a COVID-19 positive donor kidney can be acceptable. Patients should learn about the transplant center’s criteria for accepting COVID-19 positive donor kidneys at the time of listing, so that they’re not processing this information for the first time at kidney offering, when a rapid response is needed.”

 
 

During the COVID-19 pandemic, transplantation of COVID-19 infected deceased donor kidneys gradually increased from 2020 to 2021 in the United States, before spiking in the first quarter of 2022, investigators revealed at Kidney Week 2022, the annual meeting of the American Society of Nephrology, in Orlando, Florida. Recipients of COVID-19 positive donor kidneys had no worse graft outcomes than other recipients. A total of 1731 (67.7%) COVID-19 positive kidneys were transplanted, 714 (27.9%) were recovered but not transplanted, and 108 (4.2%) were not recovered at all, Warren McKinney, PhD, of Hennepin Healthcare Research Institute, University of Minnesota in Minneapolis reported on behalf of his team. He told Renal & Urology News that “high discard rates for COVID-positive donors and greater cold ischemic times may suggest that such donor kidneys remain difficult to place. Patient- and transplant program-level interventions targeting decision support and risk aversion may be necessary to reduce discard rates for COVID-positive donor kidneys.” Co-investigator and Hennepin Healthcare Research Institute President, Ajay Israni, MD, MS, added: “Nephrologists should assure transplant candidates that a COVID-19 positive donor kidney can be acceptable. Patients should learn about the transplant center’s criteria for accepting COVID-19 positive donor kidneys at the time of listing, so that they’re not processing this information for the first time at kidney offering, when a rapid response is needed.”

 
 

October

Patients suffering a medical cardiac arrest stand a significantly better chance of surviving to discharge neurologically intact from a hospital if they receive a head and shoulder elevation approach to cardiopulmonary resuscitation – especially the if initial treatment using the new approach is started in less than 18 minutes after the 911 call for help is received, according to a new study. A clinical paper published in the scientific journal Resuscitation states that irrespective of initial cardiac rhythm, even Asystole/Pulseless Electrical Activity, ACE-CPR was associated with higher adjusted odds ratios of survival to hospital discharge relative to conventional supine CPR (C-CPR) when initiated within 18 minutes of the call. The researchers who are from HHRI and HHS are:

  1. Johanna C. Moore, MD, Hennepin Healthcare, Minneapolis, MN; University of Minnesota, Minneapolis, MN; Hennepin Healthcare Research Institute Minneapolis, MN
  2. Bayert Salverda, Hennepin Healthcare Research Institute Minneapolis, MN
  3. Paul Nystrom, MD, Hennepin Healthcare, Minneapolis, MN; Hennepin Healthcare, Minneapolis, MN
  4. Ryan Quinn, Hennepin Healthcare, Minneapolis, MN
  5. Keith G Lurie, MD, Hennepin Healthcare, Minneapolis, MN; University of Minnesota, Minneapolis, MN; Hennepin Healthcare Research Institute Minneapolis, MN
 
 

September

In their report, authors Nicholas S Roetker (Hennepin Healthcare Research Institute, Minneapolis, USA) and colleagues write that the risks of major bleeding, thrombosis, and cardiovascular events are elevated in patients receiving maintenance haemodialysis. The team’s objective was to compare the risk of these outcomes in haemodialysis patients according to the permanent vascular access type. Using data from the United States Renal Data System (2010–2015), the researchers included in their study patients with kidney failure who were greater than 18 years, had Medicare as the primary payer, were not using an oral anticoagulant, and were newly using an arteriovenous (AV) access for haemodialysis. The investigators acknowledge some limitations of their study, noting for example that the analysis included only patients with a functioning AV access, and that the scope of outcomes considered provides an “incomplete picture” of the risks facing AV access users. “While this analysis was primarily concerned with assessing bleeding, thrombotic, and cardiovascular events, the risk of a variety of other serious clinical outcomes should be considered when choosing a vascular access,” they write. Furthermore, the authors note that their study included Medicare fee-for-service beneficiaries with Part D coverage who were not receiving oral anticoagulation; as such, they comments that “the results may not be generalisable to other kidney failure populations”.

 
 

August

Scientists have found that metformin, a commonly prescribed diabetes medication, lowers the odds of emergency department visits, hospitalizations, or death due to COVID-19 by over 40 percent; and over 50 percent if prescribed early in onset of symptoms. The study, which was published on August 18 in the New England Journal of Medicine, also found no positive effect from treatment with either ivermectin or low-dose fluvoxamine. The research was led by the University of Minnesota Medical School and School of Public Health along with others from Hennepin Healthcare and HHRI. “We are pleased to contribute to the body of knowledge around COVID-19 therapies in general, with treatments that are widely available. Our trial suggests that metformin may reduce the likelihood of needing to go to the emergency room or be hospitalized for COVID-19,” said Carolyn Bramante, MD, principal investigator of the study. The clinical trial launched in January 2021 after U of M Medical School scientists identified, through computer modeling and observational studies, that outpatient metformin use appeared to decrease the likelihood of mortality from, or being hospitalized for, COVID-19. Hennepin Healthcare was one of the participating clinical trial sites. Researchers included Mike Puskarich, MD, MS.

 

The Hennepin Healthcare Research Institute is evaluating an unusual methodology of quitting smoking by allowing participants to wager on themselves and put staunch money. It's miles a fraction of a label-unusual game called QuitBet, which is supported by a National Institutes of Health (NIH) analysis grant that is being administered by scientists at Hennepin Healthcare. Avid gamers wager $30 on themselves, which is added to the pot, and decide to stopping smoking for four weeks. After that, gamers in discovering a free breath checking out tool to video show their day-today development. All the gamers who accumulate been able to pause smoking on the tip divide the pot with the assorted winners, winning inspire their customary wager plus a profit. Most winners who stop smoking double their winnings. Scientific enhance is being given by Sandra Japuntich, Ph.D., a Hennepin Healthcare Investigator. “We’ve known for years that paying of us to alternate behaviors, is known as contingency management, works to wait on of us pause smoking. Alternatively, enforcing contingency management in a sustainable methodology is refined. QuitBet solves this by having players self-fund their very delight in incentives,” acknowledged Dr. Japuntich.

 
 

July

Among permanent vascular access options for hemodialysis, arteriovenous grafts carry a higher risk for venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, compared with arteriovenous fistulas. Using information from the 2010-2015 US Renal Data System, investigators compared 17,763 new recipients of arteriovenous grafts and 60,329 recipients of arteriovenous fistulas. Over 3 years, 10.8 vs 5.3 VTE events per 100 person-years occurred in the arteriovenous grafts vs arteriovenous fistulas groups, respectively. After adjustment for potential confounders, arteriovenous grafts were significantly associated with a 74% higher risk for VTE compared with arteriovenous fistulas, Nicholas S. Roetker, PhD, MS, of Hennepin Healthcare Research Institute in Minneapolis, Minnesota, and colleagues reported in Kidney Medicine.

 

Compared with the use of an arteriovenous fistula, the use of an arteriovenous graft in dialysis is associated with an increased risk of venous thromboembolism, according to data published in Kidney Medicine. “Compared with the general population, patients with kidney failure receiving maintenance hemodialysis face higher risks of both bleeding and thrombosis,” Nicholas S. Roetker, PhD, MS, from the Chronic Kidney Disease Research Group at Hennepin Healthcare Research Institute in Minnesota, and colleagues wrote. They added, “Although an arteriovenous (AV) fistula is generally preferred to an AV graft to minimize vascular access complications, given recent guidelines suggesting tailoring the access type to the clinical circumstances of each patient, a better understanding of the risks of bleeding, thrombosis, and other cardiovascular endpoints could help guide the choice of the type of permanent AV access.” Researchers identified 10.8 venous thromboembolism events per 100 person-years among patients using AV grafts, whereas 5.3 venous thromboembolism events per 100 person-years occurred among patients using AV fistulas. Therefore, the use of AV grafts in hemodialysis correlated with an increased risk of venous thromboembolism compared with AV fistulas. Additionally, analyses revealed AV graft use potentially correlated with an increased risk of cardiovascular death.

 

The Hennepin Healthcare Research Institute is studying the new method of quitting smoking by allowing participants to play a game, called QuitBet. It is quite simple – bet on yourself and win money if you could successfully stay away from cigarettes. The participants can place of bet of $30 on themselves and win the money back, along with a profit if they could manage to refrain from smoking for at least four weeks. The money collected from the participants will be added to a pot and it will be divided among the winners at the end of that period. Most participants who quit smoking will get double the amount they invested. This innovative game was developed by WayBetter. It was part of a series of "serious games" funded by the National Institutes of Health (NIH) aimed at improving people's health and lifestyle in a fun way. Other such games include DietBet, a weight loss game, and StepBet, which will track your steps. The NIH has provided $1.15 million for the QuitBet research. "We've known for years that paying people to change behaviors, known as contingency management, works to help people stop smoking. However, implementing contingency management in a sustainable way is difficult. QuitBet solves this by having players self-fund their own incentives," said Sandra Japuntich, Ph.D., a Hennepin Healthcare investigator who was part of the study.

 

The Hennepin Healthcare Research Institute is studying the new method of quitting smoking by allowing participants to play a game, called QuitBet. It is quite simple – bet on yourself and win money if you could successfully stay away from cigarettes. The participants can place of bet of $30 on themselves and win the money back, along with a profit if they could manage to refrain from smoking for at least four weeks. The money collected from the participants will be added to a pot and it will be divided among the winners at the end of that period. Most participants who quit smoking will get double the amount they invested. This innovative game was developed by WayBetter. It was part of a series of "serious games" funded by the National Institutes of Health (NIH) aimed at improving people's health and lifestyle in a fun way. Other such games include DietBet, a weight loss game, and StepBet, which will track your steps. The NIH has provided $1.15 million for the QuitBet research. "We've known for years that paying people to change behaviors, known as contingency management, works to help people stop smoking. However, implementing contingency management in a sustainable way is difficult. QuitBet solves this by having players self-fund their own incentives," said Sandra Japuntich, Ph.D., a Hennepin Healthcare investigator who was part of the study.

 

The Hennepin Healthcare Research Institute is evaluating a novel method of quitting smoking by allowing participants to wager on themselves and earn real money. It is a part of a brand-new game called QuitBet, which is supported by a National Institutes of Health (NIH) research grant that is being administered by scientists at Hennepin Healthcare. Players bet $30 on themselves, which is added to the pot, and commit to stopping smoking for four weeks. After that, players get a free breath testing device to monitor their daily progress. All of the players who were able to stop smoking at the end divide the pot with the other winners, winning back their original wager plus a profit. Most winners who give up smoking double their winnings. The principal investigator for the study is Jamie Rosen, founder and CEO of WayBetter. Scientific support is being given by Sandra Japuntich, Ph.D., a Hennepin Healthcare Investigator. The National Institutes of Health provided $1.15 million in funding to help the research. “We’ve known for years that paying people to change behaviors, known as contingency management, works to help people stop smoking. However, implementing contingency management in a sustainable way is difficult. QuitBet solves this by having players self-fund their own incentives,” said Dr. Japuntich.

 

June

Hennepin Healthcare Research Institute is testing this new innovative way to help people quit smoking by letting them bet on themselves and win real money. The new game is called QuitBet and it is being funded by a National Institutes of Health research grant. Players commit to quit smoking over four weeks and bet $30 on themselves, which goes into the pot. You then get a free breath testing device to track your daily progress. In the end, all the players who managed to quit smoking for the four weeks win their money back plus they split the pot with the other winners. They say winners typically double their money.

 

Minnesota cigarette smokers who are trying to quit the habit have the opportunity to bet on themselves and earn some cash in the process. The Hennepin Healthcare Research Institute, which oversees the medical research at Hennepin County Medical Center, is currently testing the new method to help people during that challenging process, called "QuitBet." It's a game funded by the National Institutes of Health (NIH) — features participants betting $30 on themselves to quit smoking over a four-week period. “We’ve known for years that paying people to change behaviors, known as contingency management, works to help people stop smoking. However, implementing contingency management in a sustainable way is difficult. QuitBet solves this by having players self-fund their own incentives,” said Dr. Sandra Japuntich, who is a Hennepin Healthcare investigator providing scientific support on the project.

 

May

Minnesota cigarette smokers who are trying to quit the habit have the opportunity to bet on themselves and earn some cash in the process. The Hennepin Healthcare Research Institute, which oversees the medical research at Hennepin County Medical Center, is currently testing the new method to help people during that challenging process, called "QuitBet." It's a game funded by the National Institutes of Health (NIH) — features participants betting $30 on themselves to quit smoking over a four-week period. “We’ve known for years that paying people to change behaviors, known as contingency management, works to help people stop smoking. However, implementing contingency management in a sustainable way is difficult. QuitBet solves this by having players self-fund their own incentives,” said Dr. Sandra Japuntich, who is a Hennepin Healthcare investigator providing scientific support on the project.

New game helps people to quit smoking. The game lets people bet on themselves and win real money, reveal researchers from Hennepin Healthcare Research Institute. It's part of a new game called QuitBet and it's being funded by a National Institutes of Health (NIH) research grant administered by researchers at Hennepin Healthcare. Jamie Rosen, WayBetter's founder and CEO, is the Principal Investigator of the study. Sandra Japuntich, PhD, a Hennepin Healthcare Investigator, is providing scientific support. The study was funded with $1.15 million from the National Institutes of Health. "We've known for years that paying people to change behaviors, known as contingency management, works to help people stop smoking. However, implementing contingency management in a sustainable way is difficult. QuitBet solves this by having players self-fund their own incentives," said Dr. Japuntich.

Michael Culhane had messed up in an EMT practice exercise, and his trainer was letting him know it. There is a cadence and order to the questions that medics ask on emergency scenes, and the 47-year-old firefighter had scrambled them. The criticism was harsh and true, and Culhane was happy to hear it. After nine months in COVID-19 recovery — after receiving overwhelming support to sit up, then stand, then walk again — he wasn't getting sympathy points here. Culhane shared his recovery story this week after returning to HCMC in Minneapolis to thank the caregivers who helped save his life — people he didn't really recognize because he was in a sedated coma during his three-month hospitalization. Culhane was placed on a ventilator at HCMC. His oxygen levels would improve when rolled onto his stomach but plummet when returned to his back. He was recommended for extracorporeal membrane oxygenation, or ECMO, a bypass machine that filters blood when the lungs can't keep pace. The death rate of COVID-19 patients on ECMO is 47%, according to an international registry, but Culhane was running out of options. "He was frankly lucky that his body responded the way it did," said Dr. Matthew Prekker, an HCMC critical care specialist.

The Hennepin Healthcare Research Institute is testing an innovative way to help people quit smoking – by allowing them to bet on themselves and win real money. It is part of a new game called QuitBet and is funded by a National Institutes of Health (NIH) research grant administered by researchers at Hennepin Healthcare. Players commit to quit smoking over four weeks and bet $30 on themselves that goes into the pot. Players will then receive a free breath test device to track their progress each day. In the end, all players who managed to quit will win back their stake and a win as they share the pot with the other winners. Winners usually double their money when they quit smoking. Jamie Rosen, founder and CEO of WayBetter, is the lead investigator on the study. Sandra Japuntich Ph.D., a Hennepin Healthcare Investigator, provides scientific support. The study received $1.15 million in funding from the National Institutes of Health. “We’ve known for years that paying people for behavior changes, known as emergency management, helps them quit smoking. However, it is difficult to implement emergency management in a sustainable manner. QuitBet solves this problem by allowing players to self-fund their own incentives,” said Dr. Japuntich.

Read the story on Fior Reports.

Hennepin Healthcare Research Institute is testing an innovative way to help people quit smoking – by letting them bet on themselves and win real money. It's part of a new game called QuitBet and it's being funded by a National Institutes of Health (NIH) research grant administered by researchers at Hennepin Healthcare. Players commit to quit smoking over four weeks and bet $30 on themselves, which goes into the pot. Players then receive a free breath testing device to track their progress every day. At the end, all the players who have managed to quit win back their bet plus a profit as they split the pot with the other winners. Winners typically double their money while quitting smoking. Jamie Rosen, WayBetter's founder and CEO, is the Principal Investigator of the study. Sandra Japuntich Ph.D., a Hennepin Healthcare Investigator, is providing scientific support. The study was funded with $1.15 million from the National Institutes of Health. "We've known for years that paying people to change behaviors, known as contingency management, works to help people stop smoking. However, implementing contingency management in a sustainable way is difficult. QuitBet solves this by having players self-fund their own incentives," said Dr. Japuntich.

Read the story on Best Health Article.

Hennepin Healthcare Research Institute is testing an innovative way to help people quit smoking – by letting them bet on themselves and win real money. It’s part of a new game called QuitBet and it’s being funded by a National Institutes of Health (NIH) research grant administered by researchers at Hennepin Healthcare. Players commit to quit smoking over four weeks and bet $30 on themselves, which goes into the pot. Players then receive a free breath testing device to track their progress every day. At the end, all the players who have managed to quit win back their bet plus a profit as they split the pot with the other winners. Winners typically double their money while quitting smoking. Jamie Rosen, WayBetter’s founder and CEO, is the Principal Investigator of the study. Sandra Japuntich Ph.D., a Hennepin Healthcare Investigator, is providing scientific support. The study was funded with $1.15 million from the National Institutes of Health.

Read the story on ScienMag Science Magazine.

Hennepin Healthcare Research Institute is testing an innovative way to help people quit smoking – by letting them bet on themselves and win real money. It's part of a new game called QuitBet and it's being funded by a National Institutes of Health (NIH) research grant administered by researchers at Hennepin Healthcare. Jamie Rosen, WayBetter's founder and CEO, is the Principal Investigator of the study. Sandra Japuntich Ph.D., a Hennepin Healthcare Investigator, is providing scientific support. The study was funded with $1.15 million from the National Institutes of Health.

Read the story on News Medical Life Sciences.

The Scientific Registry of Transplant Recipients (SRTR) held a consensus conference in 2012 that examined methods used by SRTR for constructing performance metrics and made recommendations on how to improve program-specific reports. During the subsequent decade, SRTR has implemented most of these recommendations; these are described in this article along with plans for another consensus conference in 2022. 

Read the article on  Physician's Weekly

HHRI Researcher, Sandra Japuntich, PhD, LP, was on WCCO 830-AM radio. Dr. Japuntich was interviewed about her woman-led cancer research where she talked about the American Cancer Society’s ResearcHERS initiative to get more women involved in cancer research. 

 

Listen to the interview on WCCO News Talk 830. Dr. Japuntich’s interview starts at about 20:45.

Healthcare insurance in the U.S. can be spotty, even with expansion of coverage under the Affordable Care Act. One of the remaining problem areas is coverage for people who are leaving prison or jail. In nonfederal cases, state and county governments pay for healthcare during the period people are incarcerated. But once they are released, there is often a gap before they get signed up for coverage by Medicaid or another payer. For people with chronic health conditions, that gap can lead to medical conditions getting out of control and acute episodes that lead to hospitalization or premature death. The federal Medicaid Reentry Act of 2021 is designed to remedy the situation. Currently, Medicaid programs are explicitly prohibited from covering incarcerated individuals. The proposed law would permit Medicaid to cover people starting 30 days before they are to be released. Advocates and public health officials say that would mean a smoother transition and increase the chances that recently incarcerated people will receive the medical services they need. But the Reentry Act could have some unintended consequences. Utsha Khatri, M.D., of the Institute for Heath Equity Research at the Icahn School of Medicine at Mount Sinai in New York and Tyler N.A. Winkelman, M.D., M.Sc., of the Health, Homelessness, and Criminal Justice Lab at the Hennepin Healthcare Research Institute in Minneapolis outlined a few of the consequences in an opinion piece published in April in the New England Journal of Medicine.

Read the story on Managed Healthcare Executive.

Label-concordant dosing may benefit patients on dialysis with nonvalvular atrial fibrillation more than below-label dosing, according to data published in the American Journal of Kidney Diseases. Further, warfarin correlated with an increased risk of bleeding compared with apixaban among this patient population. “Some patients on dialysis who have atrial fibrillation receive apixaban for stroke prevention at a dose below that indicated by the official drug label to reduce adverse bleeding events,” James B. Wetmore, MD, MS, of the chronic disease research group at the Hennepin Healthcare Research Institute in Minnesota, and colleagues wrote. They added, “Given controversy about apixaban dosing in dialysis, we used data from the United States Renal Data System (USRDS) to examine the effectiveness and safety of apixaban based on whether it was dosed in accordance with its U.S. FDA label (5 mg twice daily) or off-label at a lower dose (2.5 mg twice daily, when 5 mg was actually indicated).”

Read the story and watch the video on Healio.

April

Eric D. Weinhandl, PhD, MS, talks about the hidden costs in helping patients transition from peritoneal dialysis to home hemodialysis. “Increasing use of peritoneal dialysis (PD) will likely lead to increasing numbers of patients transitioning from PD to hemodialysis (HD),” Weinhandl, an epidemiologist at the Hennepin Healthcare Research Institute in Minneapolis at the time the research was completed, and colleagues wrote in a poster presented at the meeting. Researchers used the U.S. Renal Data System to identify patients aged 12 years and older who were newly diagnosed with end-stage kidney disease from 2001 through 2017.

Read the story and watch the video on Healio.

Hennepin Healthcare Research Institute (HHRI) announced that Warren McKinney, PhD, has been named HHRI’s VP for Equity in Research. In this role, he also joins the HHRI Board of Directors and the institute’s executive leadership team. Hennepin Healthcare is a UMN CTSA hub partner. Dr. McKinney completed CTSI’s Translational Research and Career Training (TRACT) program as a postdoctoral fellow and then went on to join the Minnesota Learning Health System Mentored Career Development Program, a K12 scholar training program at the University of Minnesota. To Dr. McKinney, CTSI has played a key role in his career. Dr. McKinney will lead the work across the Hennepin Healthcare System to connect efforts to improve health equity, define and drive strategy, and advocate for resources to build equity-focused, community-engaged research. 

 

Read the story on CTSI.

February

Tyler Winkelman, MD, MSc, provided KSTP with information from the Minnesota Department of Health (MDH) and the partnership with Hennepin Healthcare Research Institute (HHRI) and the Minnesota EHR Consortium for its story about service agencies using incentives to encourage people experiencing homelessness to get vaccinated. “The latest numbers from MDH and the Minnesota EHR Consortium show 13,246 people statewide have recently utilized a homelessness program. Of that, MDH says 5,749 people have received at least one vaccine shot, and 1,589 have received a booster, as of Feb. 5.”

 

Watch or read the story on KSTP.

A recently published study offers insight into what is being done differently at practices where patients express high trust in their clinicians and where clinicians trust their organizations. The study, published in Annals of Family Medicine, found there are four cultural variables in trusted organizations. “The emphasis on organizational culture is not an area that gets a lot of attention, but at least from these data, it’s an incredibly powerful variable that organizations should think more about,” said Mark Linzer, MD, lead author of the study, “Where Trust Flourishes: Perceptions of Clinicians Who Trust Their Organizations and Are Trusted by Their Patients.” Dr. Linzer directs the Institute for Professional Worklife and is vice chair of the medicine department at Hennepin Healthcare in Minneapolis.

Read the story on AMA.

January

Tackling the opioid crisis requires changing strategies and the way we think about addiction, says Columbia University professor Sandra Comer. That search led to a new type of treatment — a vaccine that targets the chemical makeup of oxycodone. Comer and her research colleague, Marco Pravetoni, are testing the vaccine on volunteers with substance use disorder. Dr. Pravatoni began work on the opioid vaccine when he was an investigator at the Hennepin Healthcare Research Institute (HHRI). Dr. Pravetoni left HHRI and joined the University of Minnesota in the fall of 2018. He was recently recruited from Minnesota to lead UW Medicine’s new Center for Medication Development for Substance Use Disorders.

Watch or read the story on CBS Evening News.

Dr. James Miner, chief of emergency medicine at Hennepin Healthcare and HHRI investigator, says hospitals are busier than they've ever been.

Watch the story on KARE-11.

2021

December

More than 1 million COVID-19 cases have been diagnosed in Minnesota since the pandemic began in the state nearly 22 months ago. State health officials announced another 4,155 new cases Monday, bringing the total number of infections to 1,000,361. It has taken just 27 days for the state to add 100,000 new cases. The previous 100,000 took 26 days before that, making this one of the fastest-growing surges since late last year. Booster shots could slow the spread, according to a new study using Minnesota health records. The study, believed to be the largest of its kind to evaluate booster effectiveness in the United States, used patient medical records from 11 health systems that are part of the Minnesota Electronic Health Record Consortium, which was formed to conduct large-scale research. Researchers did not have access to private information about the patients. Tyler Winkelman, MD, MSc, Anne Murray, MD, MSc, and Peter Bodurtha are authors from HHRI on this study.

 

 

Read the articles on Star Tribune and MedRxiv.

Researchers identified four characteristics that were likely to improve a physician’s trust in their organization. “Trust is an intrinsic and critically important aspect of the health care workplace. Health care workers need to believe their workplaces will watch out for them, keep them safe and provide a work environment where they can provide high-quality care for their patients,” Mark Linzer, MD, a physician with Hennepin Healthcare in Minneapolis, told Healio Primary Care. Linzer and colleagues conducted an analysis of the Healthy Work Place Study, which was a randomized trial of workplace interventions designed to improve work conditions in 34 primary care clinics in the Midwestern and Eastern United States.

 

 

Read the article on Healio.

November

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on Upper Michigan's Source.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on News Break.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on Spoke Software.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on losco County News - Herald.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on Yahoo Finance.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on NBC 12 News.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on KOLD News 13.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on WCJB.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on WCAX.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on WDTV.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on KPLC 7 News.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on KLTV 7.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on NewsChannel 10.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on Web Center Fairbanks.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on NBC Nebraska Scottsbluff.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on FOX 8.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on KWQC.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on WMBF News.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on FOX 19 Now.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on KKCO 11 News.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on Yahoo.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on Suncoast View.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on Hawaii News Now.

As the COVID-19 pandemic continues to threaten the health of communities worldwide, and health care communities seek to administer COVID vaccines en masse, patients' trust in the medical profession has never been more important. Researchers from Hennepin Healthcare and the University of Minnesota, found that patients' trust in their clinicians is connected to specific aspects of culture of the organization, and the level of trust their clinicians have in the health organization in which they work. "Lack of trust in the medical profession has implications for patient care since research from past epidemics has shown that lack of trust decreases the likelihood of patients adhering to public health recommendations," Mark Linzer, MD, et al write. "It is critical to identify factors that will assist health systems to better understand how to create the most trust within their work environments."

 

Read the article on Morningstar.

Home dialysis use has been on the rise, with greater absolute growth occurring with peritoneal dialysis (PD) and greater relative growth observed with home hemodialysis (HHD), according to data presented during the American Society of Nephrology’s Kidney Week 2021. From 2016 to 2021, home dialysis use rose from 11.6% to 14.5%, Eric D. Weinhandl, PhD, MS, of Hennepin Healthcare Research Institute in Minneapolis, Minnesota, and colleagues reported. During that same period, HHD use increased from 1.57% to 2.31% and PD use increased from 10.0% to 12.2%.

 

Read the article on Renal & Urology News.

October

For many people in their 50s, 60s, and 70s, taking a low-dose aspirin has been part of their daily routine for decades. For people without cardiovascular disease, it has long been accepted that daily low-dose aspirin lowers the odds of having a first heart attack or stroke. The idea is so ingrained among the general public that millions take “baby” aspirin without consulting their physicians. But a proposed update to the U.S. Preventive Services Task Force guidelines will likely pull back the task force's 2016 recommendations and limit daily aspirin for prevention to a more restricted group. The biggest change in 2021 is that the latest science casts doubt about aspirin’s ability to prevent colon cancer. A lot of people are unaware of this aspect of the guidelines, but the 2016 Task Force considered aspirin’s effect on colon cancer to get a more complete picture of aspirin’s potential benefits. But the ASPREE trial, which enrolled people 70 years old or older, found during the five-year trial that colon cancer risk was higher with aspirin than without it. That said, the jury is still out regarding colon cancer—any benefits of aspirin in clinical trial participants will likely take 10 or 20 more years to come to light. This means that in the future, these guidelines may change again. HHRI researcher Anne Murray, MD, MSc, is Co-PI on the ASPREE trial. 

 

Read the story on Mirage News.

For many people in their 50s, 60s, and 70s, taking a low-dose aspirin has been part of their daily routine for decades. For people without cardiovascular disease, it has long been accepted that daily low-dose aspirin lowers the odds of having a first heart attack or stroke. The idea is so ingrained among the general public that millions take “baby” aspirin without consulting their physicians. But a proposed update to the U.S. Preventive Services Task Force guidelines will likely pull back the task force's 2016 recommendations and limit daily aspirin for prevention to a more restricted group. The biggest change in 2021 is that the latest science casts doubt about aspirin’s ability to prevent colon cancer. A lot of people are unaware of this aspect of the guidelines, but the 2016 Task Force considered aspirin’s effect on colon cancer to get a more complete picture of aspirin’s potential benefits. But the ASPREE trial, which enrolled people 70 years old or older, found during the five-year trial that colon cancer risk was higher with aspirin than without it. That said, the jury is still out regarding colon cancer—any benefits of aspirin in clinical trial participants will likely take 10 or 20 more years to come to light. This means that in the future, these guidelines may change again. HHRI researcher Anne Murray, MD, MSc, is Co-PI on the ASPREE trial. 

 

Read the story on Columbia University Irving Medical Center.

In Minnesota, people of color experience some of the worst health disparities in the U.S. The Center for Chronic Disease Reduction and Equity Promotion Across Minnesota, or C2DREAM, is a new research center led by Mayo Clinic and the University of Minnesota that aims to reduce these disparities in collaboration with Minnesota community leaders and community health organizations. "The C2DREAM research center will evaluate novel interventions designed to address structural and interpersonal racism as a fundamental cause of cardiovascular health disparities among people of color in rural and urban communities in Minnesota," says Christi Patten, Ph.D., a Mayo Clinic behavioral health researcher and co-principal investigator for C2DREAM. C2DREAM is a regional effort spanning Minnesota that includes Mayo Clinic, Southeast; Mayo Clinic Health System, South and Southwest; the University of Minnesota, Hennepin Healthcare, and Native American Community Clinic, Central and North; and the Rand Corp. It brings together researchers and community stakeholders from various disciplines, drawing on evidence-based medical expertise and local and cultural knowledge.

 

Read the article on Post Bulletin.

Rochester, Minn.-based Mayo Clinic and the University of Minnesota in Minneapolis have received a five-year, $19.4 million grant from the National Institute on Minority Health and Health Disparities to create a research center aimed at reducing heart health disparities. The Center for Chronic Disease Reduction and Equity Promotion Across Minnesota will work with community partners to support clinical research on community and primary care approaches to diet, physical activity, smoking cessation and other factors related to heart health disparities. Additionally, the program will explore the root causes of health inequities, according to an Oct. 19 news release. 

 

Read the article on Becker's Hospital Review.

The University of Minnesota and Mayo Clinic have received a $19.4 million federal grant to start a new research center that will focus on racial disparities in cardiovascular health. The five-year grant from the National Institute on Minority Health and Health Disparities will be used to support clinical research on community and primary care approaches to diet, physical activity, smoking cessation and other factors that impact heart health. Hennepin Healthcare Research Institute is among the organizations that will collaborate with the new research initiative.

 

Read the article on Star Tribune.

The University of Minnesota and Mayo Clinic have received a $19.4 million federal grant to start a new research center that will focus on racial disparities in cardiovascular health. The five-year grant from the National Institute on Minority Health and Health Disparities will be used to support clinical research on community and primary care approaches to diet, physical activity, smoking cessation and other factors that impact heart health. Hennepin Healthcare and the Native American Community Clinic in south Minneapolis are among the organizations that will collaborate with the new research initiative.

 

Read the article on Yahoo Entertainment.

Research has shown the effectiveness of aspirin in the secondary prevention of cardiovascular disease among persons with a history of coronary heart disease. The evidence of primary prevention is less conclusive, despite some studies showing that aspirin reduces the incidence of cardiovascular events and possibly reduces the incidence of cancer and cancer-associated mortality. In this study, scientists conducted the Aspirin in Reducing Events in the Elderly (ASPREE) randomized, placebo-controlled trial across 34 sites in the United States and 16 sites in Australia. Trial subjects were community-dwelling men and women from Australia and the United States. A total of 19,114 persons were enrolled in the study, of whom 9,525 were randomly assigned to receive aspirin. The participants were 70 years of age or older (≥65 years of age for blacks and Hispanics in the U.S.) and were free of any chronic illness. White participants comprised 91% of the study cohort. Additionally, 56.4% of the participants were women and 11.0% reported previous regular aspirin use. HHRI researcher Anne Murray, MD, MSc, is Co-PI on the ASPREE trial. 

 

Read the article on News Medical Life Science.

September

The number of patients starting treatment for end-stage kidney disease (ESKD) in the US dropped sharply during the first wave of the COVID-19 pandemic, with the most pronounced decline occurring among individuals aged 75 years or older, according to a new study. “The abrupt decline in documented ESKD incidence is unprecedented: the approximately 2200 persons per week known to reach ESKD during the initial height of the pandemic has not been observed since 2011,” James B. Wetmore, MD, MS, of the Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, and colleagues reported in the Journal of the American Society of Nephrology. During the initial height of the pandemic (epidemiologic weeks 15-18; April 2020), the documented incidence of ESKD decreased by 25% overall and 31% among those aged 75 years or older compared with corresponding periods in 2017-2019.

 

Read the article on Renal & Urology News.

zAmya Theater brings people with (and without) experience around homelessness together around theater, community, advocacy and social justice. For this production, zAmya worked with Dr. Kate Diaz Vickery Diabetes + Homelessness Research Team from Hennepin Healthcare Research Institute. They did a staged reading of the play at the Capri Theatre in North Minneapolis. Dr. Vickery has been working on research and prevention of diabetes, especially with people experiencing homelessness for many years. Her team went to a zAmya production before the pandemic and a lightbulb popped. She realized that theatre might be an effective way to get the message to the target market. The show was much more engaging and memorable than a brochure.

 

Read the article on Mostly Minnesota.

August

Imagine you’ve been on a waiting list for a new liver for years. When you learned you would need an organ transplant, your head was spinning. You were sent to a transplant center, where you underwent a lengthy evaluation process to determine your eligibility to be placed on the waiting list for a new liver. Three and a half years later, your phone rings in the middle of the night. It’s your transplant center, calling to offer you a liver! Finally, the moment you’ve been waiting for. But wait — the nurse coordinator on the other end of the line is explaining that the organ you’re being offered came from someone who died of a drug overdose, although test results don’t show any signs of infection. “The current process for matching an organ to a patient isn’t very patient-friendly,” says Cory Schaffhausen, PhD, a researcher at Hennepin Healthcare Research Institute, assistant professor at University of Minnesota Medical School, and human-centered design engineer at the Scientific Registry of Transplant Recipients (SRTR), a data registry located at Hennepin Healthcare that analyzes outcomes for organ transplant donors and recipients across the U.S. He set out to change that in 2020 with his research and design project, Embedding Human-Centered Design and Learning Health System Research in the Transplantation System.

 

Read the story on UMN.

Things have looked up for U.S. kidney transplant recipients over the past few decades, according to a review article. In adult kidney transplant recipients, the total number of transplants from living and deceased donors in the U.S. jumped from 45,008 in 1996-1999 up to 76,885 in 2016-2019, reported Sundaram Hariharan, MD, of the University of Pittsburgh School of Medicine, and colleagues. This uptick was largely driven by a rise in the number of transplants from deceased kidney donors, from 29,823 in 1996 to 53,139 in 2019, they stated in the New England Journal of Medicine.

 

Read the article on MedPage Today.

An ongoing COVID-19 clinical trial studying the outpatient use of metformin, a generic medication for type 2 diabetes, has expanded and will now be the nation’s first to include fluvoxamine, an antidepressant, and ivermectin, an antiparasitic, as possible treatment options to prevent hospitalization and “long COVID.” Hennepin Healthcare in Minneapolis is a participating Clinical trial site.

 

Read the article on The Gilmer Mirror.

The University Hospital Center for Advanced Liver Diseases and Transplantation program was rated the top program for the second consecutive evaluation period for one-year survival rates in the Tri-state area by the Scientific Registry of Transplant Recipients. The program led by Rutgers New Jersey Medical School physicians has an estimated one-year survival rate of nearly 99 percent. Since 1989, the center for Advanced Liver Diseases and Transplantation has completed more than 1,500 liver transplant surgeries. In the past two years, the center performed over 80 transplants. The Scientific Registry of Transplant Recipients is a federally supported program for organ transplantation in the country. It is operated by the Chronic Disease Research Group and is a division of the Hennepin Healthcare Research Institute

 

Read the article on Tap into Newark.

For the second consecutive evaluation period, the Scientific Registry of Transplant Recipients (SRTR) has rated the liver transplant program at Newark’s University Hospital Center for Advanced Liver Diseases and Transplantation, as the regional leader in one-year survival rates. The Center is led by the nationally-recognized physicians at Rutgers New Jersey Medical School. With an estimated one-year survival rate of 98.75%, the Center was rated as one of the top centers from all hospitals in the New York Tri-State area of New Jersey, New York and Connecticut. The SRTR, operated by the Chronic Disease Research Group, a division of the Hennepin Healthcare Research Institute, is a federally supported program. Evaluations of liver transplant programs are released twice a year, in January and July.

 

Read the article on New Jersey Business.

July

The number of patients receiving treatment for end-stage kidney disease in April was 0.6% lower than a year ago, the first such year-to-year drop in patient census since 1980, a new study shows. “Between week 1 of 2015 and week 13 of 2020, the numbers of dialysis and transplant patients steadily increased, with little deviation from quadratic trends,” Eric D. Weinhandl, PhD, MS, and colleagues from the Chronic Disease Research Group at the Hennepin Healthcare Research Institute in Minneapolis, wrote.

 

 

Read the article on Healio.

Black patients and patients with limited English language proficiency were more likely to get a COVID-19 test initiated in an in-person healthcare setting than via telehealth, according to data published in JAMA Network Open that emphasizes how social determinants of health affected COVID-19 testing access during the pandemic. The report, completed by researchers from the University of Minnesota and Hennepin Healthcare Research Institute (HHRI), particularly investigated health disparities in some of the emerging care access modalities made prominent by the COVID-19 crisis. This isn’t because getting an ED-based test is better or worse care; rather, the disparity likely stems from the already poor health experienced by the individual admitted for inpatient care. This demonstrates how barriers to various care access modalities can affect downstream health outcomes, according to Peter Bodurtha, a data scientist with HHRI who worked on the study.

 

 

Read the article on Patient Engagement Hit

The opioid epidemic led to a record number of drug overdoses in the United States last year. The spike is happening in Minnesota, too. Just under 800 Minnesotans died from drug overdoses in 2019. More than 1,000 died last year — a 35% jump. When a lot of the world was shutting down due to the pandemic, the counselors at the Alliance Wellness Clinic in Bloomington stayed open to help people struggling with opioid addiction. Yussuf Shafie owns the clinic. Dr. Gavin Bart, an addiction medicine specialist at Hennepin Healthcare and HHRI researcher, says deadly overdoses from illicitly manufactured opiates like fentanyl are way up in Minnesota.

Read the story on CBS Minnesota

A recent study from researchers at the University of Minnesota and Hennepin Healthcare Research Institute (HHRI) is among the first to examine how different socio-demographic groups used telehealth, outpatient (i.e., clinic), emergency department and inpatient (i.e., hospital) care to test for SARS-CoV-2, the virus that causes COVID-19. Their findings were recently published in JAMA Network Open. The study was led by U of M School of Public Health along with others from Hennepin Healthcare and HHRI. Researchers included Tyler Winkelman, MD, MSc, and HHRI Data Scientist Peter Bodurtha. The team analyzed anonymous electronic health record data for people with symptoms of viral illness who received SARS-CoV-2 testing at Hennepin Healthcare, a large safety-net health system in Minneapolis. The researchers also added that the inequities could be partially explained by clinician and clinic variations in telehealth use. “Without structural reforms, rapid implementation of telehealth and other new services may exacerbate inequities in access to care, particularly if these investments come at the expense of other care sites,” said Bodurtha.

Read the article on UMN.

April

A Penn Medicine study found that Medicaid expansion helped increase access to medication for opioid use disorder, despite some existing limitations to widespread access. The study, led by Perelman School of Medicine fellow Utsha Khatri, found that Medicaid expansion correlates to significant improvements in accessing medication for OUD. Previous clinical studies have found that medications for opioid use disorder result in more effective outcomes for retention in treatment, reduced illicit opioid use, decreased opioid-related overdose rates, and serious acute care. “Medicaid alone will not entirely close gaps in care between people with and without criminal justice involvement. Additional work is needed to understand key drivers of the persistent disparities we identified,” senior author Tyler Winkelman, Co-Director of the Health, Homelessness, and Criminal Justice lab at the Hennepin Healthcare Research Institute, told Penn Medicine News. 

Read the article on The Daily Pennsylvanian.

March

A record number of Hennepin County residents fatally overdosed from opioids or methamphetamines last year, with an alarming spike in deaths from fentanyl, a powerful synthetic painkiller that can be lethal even in tiny doses. Hennepin County recorded 285 opioid-related deaths for the year, with nearly all involving at least trace amounts of fentanyl. That is up from 170 opioid deaths the year before. Methamphetamine overdoses reached a record 116 in the county last year. Methamphetamine use surged during the pandemic because the drug is more accessible and cheaper to buy, said Dr. Tyler Winkelman, a physician who treats inmates with substance abuse issues at the Hennepin County jail. With opioid and methamphetamine abuse worsening in Hennepin County, COVID-19 has scared people away from seeking treatment, he said.

 

Read the article on Star Tribune.

2020

August

The immune system overreaction to COVID-19 has become a key target for therapeutic research, including a new trial at the University of Minnesota using stem cells to try to suppress the body’s response to infection and repair the damage it causes. A COVID-19 Treatment Guidelines team formed by the National Institutes of Health has reviewed evidence for using mesenchymal stem cells to treat this hyperimmune response but does not recommend them outside of clinical trials. “It’s very much not ready for clinical implementation and clinical use,” said Dr. Jason Baker, a Hennepin Health doctor who is part of the NIH review team. “There is potential, but it very much needs to be proven.”

Read the story on Star Tribune.

Preliminary research by Mayo Clinic shows that high-dose plasma therapy is correlated with fewer deaths in patients with severe COVID-19. A 10 percentage point difference in deaths was found when comparing hospitalized COVID-19 patients who received donor plasma with high concentrations of virus-fighting antibodies compared with those who received lower concentrations, Mayo reported. HCMC in Minneapolis and Regions routinely screen COVID-19 patients shortly after admission for their interest and eligibility for convalescent plasma. “We’re all kind of waiting for more standard products to come out where you know how much antibody that someone is getting,” said Dr. Anne Frosch, who is leading HCMC’s COVID-19 convalescent plasma program.

Read the story on Star Tribune.

Published in the peer-reviewed journal Health Affairs, “Practice and Policy Reset Post-COVID-19: Reversion, Transition or Transformation?” was written by Christine Sinsky, MD, vice president of professional satisfaction at the AMA, and AMA member Mark Linzer, MD, director of the Institute for Professional Work Life at Hennepin Healthcare and professor of medicine at the University of Minnesota in Minneapolis. The commentary examines actions by regulators and payers to modify policies and lift administrative and technological burdens that allow health professionals to meaningfully care for patients with COVID-19. Most ambulatory visits are now being conducted through telehealth and in places where COVID-19 is surging, there is a need for all hands-on deck. This has led health professionals to take on new roles to meet the demand. To support these changes, the Center for Medicare and Medicaid Services (CMS) and other regulators and payers have modified longstanding policies, eliminated some nonessential administrative tasks and reduced preexisting constraints on team-based care.

Read the story on AMA.

July

When Jennifer Bennetch noticed boarded-up houses seemingly everywhere in North Philadelphia, she began documenting them. She noted their addresses and followed up to see the status of the properties: whether new residents had moved in, or if the houses were being renovated or brought to auction. She ultimately found that the owner of the properties, the Philadelphia Housing Authority (PHA), had no plans but to let them sit idle—so, in March, she quietly began moving in families. Moms 4 Housing has framed their fight for housing as a human right; their claim to secure and affordable housing is shaped through their identity as mothers with children in their care. Their demand for a home in which they can securely dwell and raise their family is a core component of reproductive justice, defined by SisterSong as the “right to maintain personal bodily autonomy, have children, not have children, and parent them in safe and sustainable communities.” Housing functions as an “anchor that families require to build security in terms of shelter, food, education, childcare, and employment,” Dr. Diana Cutts, a pediatrician and co-lead principal investigator for the research group Children’s HealthWatch, told Rewire.News.

 

Read the story on Rewire News.

April

Medical experts have for weeks tested the degree to which anti-viral treatments such as hydroxychloroquine and remdesivir can prevent the coronavirus from gaining ground inside a patient’s body. With a boost from Bill Gates, two doctors at the University of Minnesota Medical School are challenging the medical community to try a different approach — treatment studies involving common high-blood pressure medications. “This is different than doing what most of the other clinical trials are trying to do right now,” said Dr. Michael Puskarich, associate professor in the Department of Emergency Medicine at the University and emergency physician at Hennepin Healthcare. “We’re looking at more of the downstream consequences of the virus.” The doctors have launched two multi-site inpatient and outpatient clinical trials involving the drug Losartan.

 

Read the story on Pioneer Press.

Hennepin Healthcare has launched two clinical trials for a drug to see if it will help COVID-19 patients. The trials are being doing through the Hennepin Healthcare Research Institute. “The clinical trials will help to determine if remdesivir is a safe and effective drug that can improve outcomes for patients diagnosed with COVID-19 here at Hennepin Healthcare and in the broader community,” principal investigator Dr. Jason Baker said.

 

Read the story on CBS Minnesota.

A new drug is being called a ‘ray of hope’ in treating COVID-19. "This is a medicine that directly attacks the virus," said Jason Baker, MD, MS, Hennepin Healthcare’s infectious disease director. Doctors at the Hennepin Healthcare Research Institute hope to enroll about 1,000 patients now hospitalized with moderate or severe COVID-19.

 

Read the story on MinnPost.

Initially, remesivir was developed to treat ebola but failed to stop that virus. But now it has been found that the drug affects other forms of coronavirus, including SARS and MERS. “It turned out to be very active against that virus in the lab, so it quickly escalated to human studies for the COVID outbreak,” said HHRI’s Principal Investigator Jason Baker, MD, MS. The drug, which has not been approved by the Food and Drug Administration, is administered through an IV and works by preventing the virus from growing.

 

Read the Vaaju story.

Remdesivir was originally developed to treat Ebola, but was unable to stop this virus. However, the drug has been found to affect other forms of the coronavirus, including SARS and MERS. “It was found to be very active in the laboratory against this virus, and it was therefore quickly expanded to human studies for the COVID outbreak,” said HHRI’s Principal Investigator Jason Baker, MD, MS. Hennepin Healthcare wants to determine if the drug is useful and safe.

 

Read the NewsBeezer story.

A new drug is being called a "ray of hope" in treating COVID-19. “This is a medicine that directly attacks the virus,” said Jason Baker, MD, MS, Hennepin Healthcare’s infectious disease director. “Rendesivir is one of the only direct anti-viral medicines that’s being studied in the context of COVID-19.” Doctors at the Hennepin Healthcare Research Institute hope to enroll about 1,000 patients now hospitalized with moderate or severe COVID-19. 

Read the story on KSTP.

Researchers at Hennepin Healthcare are joining sites across the world in studying a drug that could help patients who have COVID-19. The clinical trials now underway at Hennepin Healthcare will study hospitalized patients with severe and moderate cases of COVID-19. They'll get an IV of remdesivir, an experimental antiviral drug. It was created to treat Ebola, but wasn't effective for that disease. "It actually blocks the virus' ability to reproduce itself genetically. It blocks that replication," said Dr. Jason Baker, the Director of Infectious Disease at Hennepin Healthcare.

 

Read the story on KARE 11.

Hennepin Healthcare has announced it has launched two clinical trials to study the safety of using an antiviral drug created for Ebola patients on those with the coronavirus. The Hennepin Healthcare Research Institute (HHRI), the medical research organization based at Hennepin County Medical Center, says it will be trialing the drug Remdesivir on patients with moderate or severe COVID-19. "We are proud to be a site that’s conducting research on this investigational treatment,” said HHRI’s Principal Investigator Jason Baker, MD, MS.

Read the story on Bring Me The News.

A drug that is showing some early success in treating severe cases of COVID-19 is now being studied in trials by Hennepin Healthcare. The Hennepin Healthcare Research Institute has launched two trials to study the safety of remdesivir. The drug had previously been tested on humans for an Ebola treatment. It has also shown some success with in vitro and animal models against other coronaviruses strains including MERS and SARS.

Read the story on FOX 9.

Hennepin Healthcare and Mayo Clinic are participating in an international clinical trial on using the drug remdesivir to treat hospitalized COVID-19 patients. Hennepin Healthcare in Minneapolis said Friday it will have 70 patients in part of a 1,000-patient worldwide study of the potential antiviral treatment developed by Gilead Sciences in California. Mayo Clinic in Rochester is also among the 133 study locations. Remdesivir showed "antiviral activity" against other coronaviruses MERS and SARS. Gilead and Hennepin Healthcare will look at the safety and efficacy on moderate to severe cases COVID-19 in a FDA clinical study. It started on March 6 and has a primary completion date of May. Hennepin Healthcare expects results on the severe group in early May. "We are proud to be a site that's conducting research on this ... treatment," Jason Baker, MD, MS, Hennepin Healthcare Research Institute's primary investigator, said in a statement. "The clinical trials will help to determine if remdesivir is a safe and effective drug that can improve outcomes for patients diagnosed with COVID-19 here at Hennepin Healthcare and in the broader community."

Read the story on Pioneer Press.

Hennepin Healthcare and Mayo Clinic are participating in an international clinical trial on using the drug remdesivir to treat hospitalized COVID-19 patients. Gilead and Hennepin Healthcare will look at the safety and efficacy on moderate to severe cases COVID-19 in a FDA clinical study. "The clinical trials will help to determine if remdesivir is a safe and effective drug that can improve outcomes for patients diagnosed with COVID-19 here at Hennepin Healthcare and in the broader community," said Jason Baker, MD, MS, Hennepin Healthcare Research Institute’s primary investigator.

Read the story on Pioneer Press.

Kelley Baer’s schedule at the Shakopee women's correctional facility doesn’t change. Due to precautions made due to the COVID-19 pandemic, Baer’s days are stretching even longer. The gym is closed, inmates can only spend one hour outside each day, and the women are limited to 1.5 hours in the day room. “If there are strong measures in place already, like minimizing groups, isolating older or more sick patients in different parts of the prison, screening staff… it could be that the scope of coronavirus in facilities could be relatively small,” said Tyler Winkelman, MD, MSc, the co-director of the Health, Homelessness, and Criminal Justice Lab at Hennepin Healthcare Research Institute and a doctor at Hennepin County Jail. According to a notice sent to all DOC staff members, anyone who walks into a correctional facility must first be screened. That screening involves asking each staff member if they are showing symptoms such as a cough, and taking temperatures.

Read the story on Southwest News Media.

March

Upon hearing that a surge of COVID-19 cases could consume all hospital ventilators, Dr. Stephen Richardson rummaged for parts in the medical device lab at the University of Minnesota and built a homemade version. In a first test last week, the prototype kept a pig breathing for an hour and raised the prospect that low-budget ventilators could be built to solve a shortage. The makeshift ventilator was made from $150 in parts, with a motor ripped from another device and a red metal toolbox tray as its base. The university also is one arm of a multisite national trial of remdesivir, an experimental drug that failed in prior studies to treat infections from the Ebola and Marburg viruses. A third U-generated trial, awaiting FDA approval, would test whether a blood pressure-lowering medication, losartan, minimizes the damage of COVID-19. When infection stops ACE-2 receptors from working, there is a buildup of a hormone called angiotensin II that causes lungs to constrict and fluid to build up, explained Dr. Michael Puskarich, emergency physician at Hennepin Healthcare, who will be leading an arm of this trial at Hennepin Healthcare in downtown Minneapolis.

Read the article on Star Tribune.

Physicians and other health professionals are desperately needed during the global response to the COVID-19 pandemic. These individuals also represent one of the most at-risk populations for acquiring COVID-19. However, they face another risk: added stress. During these trying times, it is important to keep well-being in mind and address stress. “The impact of COVID-19 is overwhelming,” said AMA member Mark Linzer, MD, director of the Institute for Professional Work Life at Hennepin Healthcare and professor of medicine at the University of Minnesota in Minneapolis. “Everybody's wrestling with what's happening and what we can best do to take care of it.”

Read the AMA story.

The next site of a deadly coronavirus outbreak may not be a cruise ship, conference, or school. It could be one of America’s thousands of jails or prisons. Just about all the concerns about coronavirus’s spread in packed social settings apply as much, if not more, to correctional settings. In a prison, multiple people can be placed in one cell. Hallways and gathering places are often small and tight (often deliberately so, to make it easier to control inmates). There is literally no escape, with little to no space for social distancing or similar recommendations experts make to combat coronavirus. Hand sanitizer can be contraband. “We can learn what works in terms of mitigation from other countries who have seen spikes in coronavirus already, but none of those countries have the level of incarceration that we have in the United States,” Tyler Winkelman, MD, MSc, a doctor and researcher at Hennepin Healthcare and the University of Minnesota focused on health care and criminal justice, told me.

 

Read the story on Vox.

This week, a person incarcerated in King County Jail in downtown Seattle was taken to the hospital after they were suspected of having the new coronavirus. The county says there are no cases currently in the jail, but the new virus remains a huge concern for correctional facilities, particularly in outbreak hotspots like King County. With 85 confirmed cases of COVID-19, the illness caused by the virus, the county is home to the largest known hotspot of cases of the new coronavirus in the United States. It’s only a matter of time before the novel coronavirus enters a US jail or prisons, says Tyler Winkelman, MD, MSc, co-director of the Health, Homelessness, and Criminal Justice Lab at the Hennepin Healthcare Research Institute in Minneapolis. “All prisons and jails should anticipate that the coronavirus will enter their facility, and they need to have plans for monitoring and treating anyone who has symptoms,” he says.

 

Read the story on The Verge.

2019

October

Doctors at Hennepin County Medical Center are working with a research team at the University of Minnesota in order to administer hyperbaric oxygen therapy. It's part of a five year, $10 million national study funded by the National Institutes of Health. "We've demonstarted that hyperbaric oxygen improves energy production in the brain. Oxygen is really acting like a drug here," said Dr. Gaylan Rockswold, a Professor of Neurosurgery at the University of Minnesota, and principal investigator of the trial. "The sooner we get them treated the better."
 
Read and view the KARE-11 story.

Dr. Hilden brings in special guest Dr. Anne Murray to talk the serious and important topic of dementia.

Listen to the Healthy Matters podcast. 

September

Abbott announced that a high-sensitivity troponin I blood test used to detect MI has received FDA clearance. The blood test (Architect Stat) can detect very low levels of troponin, which allows physicians to assess patients within 2 to 4 hours of admission, according to a press release from the company. Results of the test are not affected by biotin interference, which is important as biotin supplements grow in popularity, according to the release. “The addition of Abbott’s high-sensitivity troponin I assay to the laboratory’s diagnostic testing menu is a great step forward to help laboratory scientists and clinicians better evaluate patients suspected of having a heart attack,” Fred. S. Apple, PhD, DABCC, co-director of the Clinical and Forensic Toxicology Laboratory at Hennepin Healthcare/Hennepin County Medical Center in Minneapolis and professor of laboratory medicine and pathology at the University of Minnesota in Minneapolis, said in the release.

Read the Healio story.

The U.S. Food and Drug Administration (FDA) cleared Abbott’s blood test to help aid in the diagnosis of heart attacks for men and women hours earlier than standard tests and marks significant progress for detecting heart attacks in women. Fred Apple, co-director of Clinical and Forensic Toxicology Laboratory at Hennepin Healthcare/Hennepin County Medical Center, said the addition of Abbott's high sensitivity troponin-I assay to the laboratory's diagnostic testing menu is a “great step forward to help laboratory scientists and clinicians better evaluate patients suspected of having a heart attack.”

Read the story on BioSpace.

A national push to treat jail inmates struggling with opioid use is fueling a dramatic increase this year in the number of Hennepin County inmates receiving treatment ...“We still have an opioid crisis, and I think the numbers will go up as more people learn about the treatment we offer,” said Dr. Tyler Winkelman, a physician with Hennepin Healthcare who works with the program. “But almost everybody I’ve treated for opioids were also using methamphetamines. So the opioid crisis is going to get more complex before it gets better.”
 
Read the StarTribune article

Abbott announced today that new research, published in the journal Circulation, found its algorithm could help doctors in hospital emergency rooms more accurately determine if someone is having a heart attack or not, so that they can receive faster treatments or be safely discharged."With machine learning technology, you can go from a one-size-fits-all approach for diagnosing heart attacks to an individualized and more precise risk assessment that looks at how all the variables interact at that moment in time," said Fred Apple, Ph.D., Hennepin HealthCare/ Hennepin County Medical Center, professor of Laboratory Medicine and Pathology at the University of Minnesota, and one of the study authors. "This could give doctors in the ER more personalized, timely and accurate information to determine if their patient is having a heart attack or not." 

Read the Yahoo Finance article.

August

Opioid addiction preventive vaccine would contain fentanyl hapten removing positive reaction to the drug. The University of Montana has received a $3.3 million contract from the National Institutes of Health (NIH) to develop an innovative vaccine targeting opioid addiction. The principal investigator on the 2-year award is Dr. Jay Evans, director of the University of Montana (UM)’s Center for Translational Medicine and a research professor in the Division of Biological Sciences. Other investigators on the award are Drs. David Burkhart, Kendal Ryter and Helene Bazin-Lee from UM in Missoula, Marco Pravetoni from the University of Minnesota, and Paul Pentel and Mark LeSage from Hennepin Healthcare Research Institute.

Read the Precision Vaccinations story.

July

Hennepin Healthcare Research Institute investigator Dr. Fred Apple, PhD, DABCC, discusses his article "Myocardial Infarction Risk Stratification With a Single Measurement of High-Sensitivity Troponin I" recently published in the Journal of the American College of Cardiology.

Read the interview on MedicalResearch.com

Gov. Tim Walz signed into law a response to Minnesota’s opioid crisis that he says holds Big Pharma accountable. In 2017, there were more than 2,000 visits to Minnesota emergency rooms for opioid-involved overdoses, with 422 Minnesotans losing their lives. Since 2010, the rate of opioid-related overdose deaths has steadily increased each year. The new law, championed in the Minnesota House by Rep. Liz Olson (DFL – Duluth), becomes effective immediately. The bill includes funding for Hennepin Healthcare’s “Project ECHO, grants for tribal nations and urban Native-American communities, and additional staff for the Bureau of Criminal Apprehension’s drug labs and trafficking enforcement efforts. It also includes reforms to drug prescribing practices, improves efforts to safely remove excess drug supplies, and increases supplies of Naloxone (Narcan) for first responders.

Read the story on Insight News.

June

A new program is underway in Hennepin County to help inmates struggling with addiction. They are now screened for opioid use disorder when they arrive at the Adult Detention Center. It started in January to connect inmates with medication assisted treatment. “The folks that we’re seeing have been struggling with their substance use disorder for at least a year, but often 10, 15 or 20 years,” said Dr. Tyler Winkelman.

View/read the story on KSTP

At Hennepin Healthcare, doctors read plenty of studies, but one that claims taking certain pills may increase your risk of dementia by as much as 50%, certainly stands out. Dr. Anne Murray works in geriatrics and conducts research of her own. She says the medical community has long suspected anticholinergic drugs, which are used to treat things like depression, Parkinson’s, incontinence, allergies and other conditions, may cause dementia later in life.

View/read the story on KARE-11

Mark Linzer, MD, Principal Investigator of the Healthy Work Place study, was interviewed on JNO Live about the study that shows trust is an important attribute to clinician satisfaction; identifies characteristics associated with gender, organizational climate. The live JAMA Network Open broadcast aired on Twitter, YouTube and Facebook.

View the interview online

Read the full study on the JAMA Network Open website

After a 5-year absence, the contract for the United States Renal Data System and its annual report will return to the Chronic Disease Research Group of the Hennepin Healthcare Research Institute. The NIH awarded the 5-year contract on June 13. The United States Renal Data System (USRDS) is a national registry that collects, analyzes and distributes information about CKD and ESRD in the United States. The first annual report was published in 1989. “We’re so excited to have our team contribute to the fight against kidney disease,” Kirsten L. Johansen, MD, director of the USRDS and of the division of nephrology at Hennepin Healthcare HCMC.

Read the story on Healio

May

The World Health Organization this week recognized burnout as an official medical diagnosis. "I think it's a really important thing that they've done this. I think that provides a foothold to begin the conversation about the workplace. What we can do to help," said Dr. Mark Linzer at Hennepin Healthcare. "Raises an important question. Now that we have a diagnosis, what can we do?"

View/read the story on KARE-11

March

Drug seizures for Minnesota's Violent Crime Enforcement Teams increased in several major drug categories in 2018. The increase in drug seizures corresponds with studies that have found a rise in drug use among Minnesotans and nationally. Dr. Tyler Winkelman of Hennepin Healthcare says research has shown that hospitalizations related to methamphetamine increased 270 percent nationally between 2008 and 2015.

Read the story on KNSI

Seizures of methamphetamine in Minnesota surged at an alarming level last year, as have confiscations of other illicit drugs, state public safety officials said, and a major bust already this year suggests the influx is not letting up.  Dr. Tyler Winkelman, a physician and researcher at Hennepin Healthcare, said the “unintended consequences of getting rid of local meth labs with the crackdown on Sudafed” — the over-the-counter product that provides a key ingredient for making meth — is “that opened up the meth cartels from Mexico.”

Read the StarTribune Story

People paralyzed from a serious injury are being given an opportunity many thought they'd lost for good. Researchers at the University of Minnesota and Hennepin Healthcare are helping them regain voluntary movement and so much more.

View/read the story on KSTP

What is the background for this study? What are the main findings?

Response: Kidney transplantation confers profound survival, quality of life, and cost benefits over dialysis for the treatment of end-stage kidney disease. Kidney transplant recipients under 65 years of age qualify for Medicare coverage following transplantation, but coverage ends after three years for patients who are not disabled.

Read the full interview with Allyson Hart MD MS, Department of Medicine, Hennepin Healthcare, University of Minnesota on MedicalResearch.com

Drug seizures for Minnesota’s Violent Crime Enforcement Teams (VCET) increased in several major drug categories in 2018, according to the Minnesota Department of Public Safety. The increase in drug seizures corresponds with studies that have found a rise in drug use among Minnesotans and nationally. According to research conducted by Dr. Tyler Winkelman of Hennepin Healthcare, hospitalizations related to methamphetamine increased nationally by 270 percent from 2008-2015, faster that any other form of substance abuse. The number of women using methamphetamine during pregnancy has increased significantly since 2008, particularly in rural areas.

Read the Austin Daily Herald story

February

Researchers from the University of Minnesota and Hennepin County hope to use a recent study regarding opioid-related deaths after incarceration to address the opioid epidemic. About one-third of opioid-related deaths in Hennepin County occurred within one year of inmates leaving jail, according to a report released by the county last month. Now, public health care officials and University researchers hope to offer care to incarcerated individuals with opioid use disorder based on the report’s recommendations. "Our workgroup made recommendations to begin treating people with opioid use disorders in county correctional facilities," said Tyler Winkelman, an author of the report, clinician-investigator with Hennepin Healthcare and assistant professor of medicine at the University. The treatment would include providing medications to incarcerated individuals with opioid use disorder and connecting them to community providers upon release.

 

A study revealed that large numbers of the inmates overdose and die shortly after they are released from custody. Dr. Tyler Winkelman, a health policy expert at Hennepin Healthcare is one of the authors of the study.” Dr. Gavin Bart, director of addiction medicine at Hennepin Healthcare is one of the advisers on the study.
 
Read the StarTribune Story
 
 

New research by a local team of doctors is proving to be life-changing for people paralyzed by spinal cord injuries. It’s giving hope to thousands who previously thought they would never walk again. It took the University of Minnesota and Hennepin Healthcare two years to get through all of the paperwork, including grant approvals. It’s especially unique because doctors are studying patients who have been paralyzed for multiple years.

Read and view the story on FOX9

They've been able to restore some function in patients with devastating spinal cord injuries. Previously, it's been possible to restore some level of function in young and healthy patients who suffered a devastating spinal cord injury within a few years of it happening. But as part of the E-STAND clinical trial, Dr. David Darrow, a neurosurgery resident at the medical school and Hennepin Healthcare, broadened the scope of patients who can qualify for epidural spinal cord stimulation (ESCS).
 

There are more than 290,000 people estimated to be living in the United States with a spinal cord injury. Previously, it has been shown that it is possible to restore some function to young and healthy patients within a few years of injury. Now, researchers show spinal cord stimulation can immediately restore some voluntary movement and autonomic functions such as cardiovascular, bowel, and bladder years after a paralyzing injury without any significant rehabilitation. "This was an opportunity to use epidural stimulation, combine my background in mathematics, collaborate with people from multiple disciplines including biomedical engineering and set up a truly innovative trial," said Dr. David Darrow, a neurosurgery resident at the University of Minnesota Medical School and a lead investigator for the E-STAND Clinical trial. He is also a senior neurosurgery resident at Hennepin Healthcare and University of Minnesota Medical Center. 

 

Read the story on News Medical

January

There are more than 290,000 people estimated to be living in the United States with a spinal cord injury. Previously, it has been shown that it is possible to restore some function to young and healthy patients within a few years of injury. Now, researchers show spinal cord stimulation can immediately restore some voluntary movement and autonomic functions such as cardiovascular, bowel, and bladder years after a paralyzing injury without any significant rehabilitation. "This was an opportunity to use epidural stimulation, combine my background in mathematics, collaborate with people from multiple disciplines including biomedical engineering and set up a truly innovative trial," said Dr. David Darrow, a neurosurgery resident at the University of Minnesota Medical School and a lead investigator for the E-STAND Clinical trial. He is also a senior neurosurgery resident at Hennepin Healthcare and University of Minnesota Medical Center. "We wanted to push the envelope for patients. Once we determined it worked, we moved on to knocking down other barriers to translation to patient care."

 

Read the Medical X Press article

There are more than 290,000 people estimated to be living in the United States with a spinal cord injury. Previously, it has been shown that it is possible to restore some function to young and healthy patients within a few years of injury. Now, researchers show spinal cord stimulation can immediately restore some voluntary movement and autonomic functions such as cardiovascular, bowel, and bladder years after a paralyzing injury without any significant rehabilitation.
 
 
 

Seasonal flu and other respiratory infections may be especially dangerous for kidney failure patients, researchers say. A new study found that influenza-like illnesses likely contribute to more than 1,000 deaths among kidney failure patients in the United States each year. These illnesses include potentially serious respiratory tract infections caused by flu and other viruses. For the study, David Gilbertson, co-director of the Chronic Disease Research Group at Hennepin Healthcare Research Institute in Minneapolis, and his colleagues reviewed 14 years of federal data.

Read the story in U.S. News & World Report

 

Community activity for influenza-like illness (ILI) is associated with seasonal variation in all-cause mortality among patients with end-stage renal disease (ESRD), according to a study published online January 24 in the Journal of the American Society of Nephrology. David T. Gilbertson, PhD, from the Hennepin Healthcare Research Institute in Minneapolis, and colleagues calculated quarterly relative mortality compared with average third-quarter (summer) death counts after addressing overall increasing trends in death due to the growing prevalent ESRD population. Linear regression models were used to assess the correlation between ILI data and mortality.

Read the HealthDay News story

In patients with kidney failure, influenza-like illness (ILI) likely contributes to more than 1,000 deaths per year. The finding, which comes from a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), points to the importance of protection against, surveillance of, and, where possible, treatment of such infections in patients with kidney dysfunction.

The extent to which ILI contributes to mortality in patients with ESRD is unclear. To investigate, David Gilbertson, Ph.D. (Hennepin Healthcare Research Institute and the University of Minnesota) and his colleagues analyzed data from the Centers for Disease Control and Prevention Outpatient ILI Surveillance Network and the Centers for Medicare & Medicaid Services ESRD database from 2000-2013.

 

Read the Medical X Press article

Flu-like illness contributed substantially to mortality for people with end-stage renal disease (ESRD), an analysis spanning 14 years of U.S. data indicated. During influenza season -- the 6 months from October to March -- excess deaths averaged more than 1,000 annually among the at-risk ESRD population, according to David Gilbertson, PhD, of the Hennepin Healthcare Research Institute and the University of Minnesota, and colleagues, pointing to influenza-like illness (ILI) as the likely reason.

 

Read the article on MedPage Today

2018

November

Kristen Philman had already been using heroin and prescription painkillers for several years when, one day in 2014, a relative offered her some methamphetamine, a chemical cousin to the stimulant amphetamine. "I didn't have any heroin at the time," says Philman, a resident of Littleton, Colo. "I thought, 'Oh this might make me feel better.' "It did, she says. Soon, she was using both heroin and methamphetamine on a regular basis.

Read the story on mprnews.org

Listen to the story

Committed to making physician burnout a thing of the past, the AMA has studied, and is currently addressing, issues causing and fueling physician burnout—including time constraints, technology and regulations—to better understand the challenges physicians face.

Mark Linzer, MD, director of the division of general internal medicine at Hennepin County Medical Center in Minneapolis, has long studied physician burnout.

“Burnout doesn’t have to be highly expensive to fix,” said Dr. Linzer, director of the HCMC Center for Patient and Provider Experience. “Preventing burnout can actually save money in the long run on recruiting and training new practice staff.”  

Read the AMA Wire story

The number of people hospitalized because of amphetamine use is skyrocketing in the United States, but the resurgence of the drug has largely been overshadowed by the nation’s intense focus on opioids.

Amphetamine-related hospitalizations jumped by about 245 percent from 2008 to 2015, according to a study published last month in the Journal of the American Medical Association. That dwarfs the rise in hospitalizations from other drugs, such as opioids, which were up by about 46 percent. The most significant increases were in Western states.

The JAMA study, based on hospital discharge data, found that the cost of amphetamine-related hospitalizations had jumped from $436 million in 2003 to nearly $2.2 billion by 2015. Medicaid was the primary payer.

Read the NBC News story

For those with a substance use disorder, the risk of death from an overdose in the two weeks after leaving prison is 10 times higher than in the general population, said Dr. Tyler Winkelman of the Minneapolis-based Hennepin Healthcare, who researches health
issues in the criminal justice system.

Read the StarTribune story

Because there has been so much attention on opioids, “we have not been properly keeping tabs on other substance use trends as robustly as we should,” said study author Dr. Tyler Winkelman, a physician at Hennepin Healthcare in Minneapolis.

View the story on ABC

The number of people hospitalized because of amphetamine use is skyrocketing in the United States, but the resurgence of the drug largely has been overshadowed by the nation’s intense focus on opioids.

Read the KHN article

The number of people hospitalized because of amphetamine use is skyrocketing in the United States, but the resurgence of the drug largely has been overshadowed by the nation’s intense focus on opioids. Amphetamine-related hospitalizations jumped by about 245% from 2008 to 2015, according to a recent study in the Journal of the American Medical Association.

Read the story on TIME

11 a.m. – MPR News at 11
An estimated 30,000 people died from opioid overdoses in the U.S. in 2017. With so many people being affected what is being done to treat addiction?

Guests: Marco Pravetoni, associate professor, Department of Pharmacology, senior investigator at the Minneapolis Medical Research Foundation in the Hennepin County Medical Center; Joseph Lee, M.D., medical director, Hazelden Betty Ford Foundation Youth Continuum.

Dr. Diana Cutts, a pediatrician from Hennepin Healthcare, part of the FoodRx program, said the dilemmas poor families face are real and wrenching.

Read the StarTribune story

October

“One of the problems with addiction treatment is that it’s generally been put on the patient to take care of on their own. We wouldn’t tell someone with cancer or heart disease to go make an appointment and hope they get better,” said Dr. James Miner, chief of emergency medicine at HCMC. “The goal now is to get people started on treatment and on the road to recovery right away.”

Read the StarTribune story

Aspirin YES or NO?  Dr. Anne Murray,  a geriatrician and the US Principal Investigator for the ASPREE study is Dr. David Hilden's guest on Healthy Matters on WCCO Radio, October 21, 2018. 

Read the Healthy Matters blog

Listen to the Healthy Matters podcast

September

Aspirin has been a top topic all week — in clinics, living rooms and offices — because
three studies challenged the guidance for certain older adults taking it daily.

The latest study, known as ASPREE, followed 15,000 healthy adults ages 70 and older
over five years. It found that those taking aspirin had no greater protection from
disabilities or heart attacks but did have higher drug-related risks of internal bleeding.

Margolis and Bloomington-based HealthPartners enrolled 250 adults. Minneapolis-based
Hennepin Healthcare led the U.S. arm of the study, which was based in Australia.

Dr. Anne Murray, the Hennepin geriatrician who led the research, has been flooded with
questions about her results: “It’s been a combination of patients and colleagues, some of
whom are taking aspirin themselves.”

Read the StarTribune story

Many older people who’ve survived a heart attack or stroke take low-dose aspirin every day to help prevent further cardiovascular problems [1]. There is compelling evidence that this works. But should perfectly healthy older folks follow suit?

Most of us would have guessed “yes”—but the answer appears to be “no” when you consider the latest scientific evidence.  Recently, a large, international study of older people without a history of cardiovascular disease found that those who took a low-dose aspirin daily over more than 4 years weren’t any healthier than those who didn’t. What’s more, there were some unexpected indications that low-dose aspirin might even boost the risk of death.

The long-awaited results of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, partly funded by NIH, were presented in three papers just published in the New England Journal of Medicine [2,3,4]. It’s the largest primary prevention study ever undertaken in healthy older people.

To take a closer look, a research team led by John McNeil, Monash University, Melbourne, Australia, and Anne Murray, Hennepin Healthcare Research Institute, Minneapolis, launched the ASPREE trial in 2010.

 

Read the NIH Director's Blog

A major international study led in part by a Minnesota physician has found that healthy
people over age 70 got no preventive benefit from aspirin and were at greater risk for
harm such as stomach bleeding. It's the third major study this year to reach a similar
conclusion.

"We hope this shifts the paradigm for people 70 and older who are considering taking
aspirin," said Dr. Anne Murray, a geriatrician at Hennepin Healthcare in Minneapolis
who led the research along with Dr. John McNeil in Australia.

Read the StarTribune story

Many heart-healthy older people take a daily baby aspirin out of a belief that it will help prevent a
heart attack or stroke. A major new study, published online Sunday in three articles in the New England Journal of Medicine (NEJM), now calls that common practice into serious question. It found that for older people with no history of heart attack, stroke or congestive heart failure taking a daily aspirin might do more harm than good.

”We found there was no discernible benefit of aspirin on prolonging independent, healthy life for the elderly,” Dr. Anne Murray, one of the authors of the study and an epidemiologist and geriatrician at Hennepin Healthcare in Minneapolis, told National Public Radio (NPR) reporter Rob Stein.

Read the MinnPost story

In healthy elderly people who never had a heart attack, the widespread practice of taking a baby aspirin every day may do more harm than good, according to a U.S.-Australian study of more than 19,000 volunteers.

The results - which show that risks of major bleeding in low-dose aspirin users overwhelm any heart benefits - were reported online in the New England Journal of Medicine and presented Sunday at the European Respiratory Society International Congress in Paris.

Read the Reuters story on FOX NEWS

It's one of the most well-known tenets of modern medicine: An aspirin a day keeps the doctor away. But according to a trio of studies published Sunday in the New England Journal of Medicine, a daily low-dose aspirin regimen provides no significant health benefits for healthy older adults. Instead, it may cause them serious harm.

Read / Watch the Story on CNN

Should older people in good health start taking aspirin to prevent heart attacks, strokes,
dementia and cancer?

No, according to a study of more than 19,000 people, including whites 70 and older, and
blacks and Hispanics 65 and older. They took low-dose aspirin — 100 milligrams — or a
placebo every day for a median of 4.7 years. Aspirin did not help them — and may have
done harm.

Read the story in The New York Times

Researchers found that taking low dose aspirin did not prevent heart attacks or cardiovascular disease in healthy people over 70, and the daily pill increased the risk of serious health complications like stomach and brain bleeding.

Watch the NBC Nightly News Story

The possible utility of aspirin for primary prevention has taken another blow with new results showing no benefit of treatment in extending disability-free survival, a novel endpoint that combines all-cause death, dementia, or physical disability, among healthy elderly persons.

A second report showed no significant reduction in cardiovascular disease but a significantly higher risk for major hemorrhage, and a third analysis showed higher all-cause mortality with aspirin therapy, mostly attributed to increased cancer risk, although the researchers urge caution in interpreting this latter finding.  

The results, from the Aspirin in Reducing Events in the Elderly (ASPREE) trial, were published online September 16 in three separate papers in the New England Journal of Medicine (NEJM).  

Read the Medscape article

Daily aspirin not only failed to help generally healthy older individuals reduce their risk of disability-free survival and cardiovascular disease in the placebo-controlled ASPREE trial, it also appeared to raise overall mortality and particularly death from cancer.

Read the story on MedPage Today

Many healthy Americans take a baby aspirin every day to reduce their risk of having a heart attack, getting cancer and even possibly dementia. But is it really a good idea?

Results released Sunday from a major study of low-dose aspirin contain a disappointing answer for older, otherwise healthy people.

"We found there was no discernible benefit of aspirin on prolonging independent, healthy life for the elderly," says Anne Murray, a geriatrician and epidemiologist at Hennepin Healthcare in Minneapolis, who helped lead the study.

Read the NPR story

Listen to the NPR interview with Dr. Murray

A regimen of low-dose aspirin “offers healthy, older people no benefit in staving off cardiovascular disease, dementia or disability and increases their risk of bleeding in the digestive tract and brain, according to a large study released Sunday.” The article says that research indicates “a regimen of low-dose aspirin offers healthy, older people no benefit in staving off cardiovascular disease, dementia or disability and increases their risk of bleeding in the digestive tract and brain.” The findings were published in three articles in the New England Journal of Medicine. In a news release, Richard J. Hodes, Director of the National Institute on Aging, said, “Clinical guidelines note the benefits of aspirin for preventing heart attacks and strokes in persons with vascular conditions such as coronary artery disease.” Hodes added, “The concern has been uncertainty about whether aspirin is beneficial for otherwise healthy older people without those conditions.” To view the NEJM articles, click here, here, and here.

Read the Washington Post story

Researchers determined that after nearly five years in treatment, participants’ “rate of heart disease was not significantly lower,” although the “rate of major bleeding with daily aspirin use was 3.8 percent, versus 2.8 percent with placebo.” Lead author Dr. John J. McNeil of Monash University commented, “Essentially, we could not identify any subgroup in whom aspirin was beneficial in preserving good health.”

Read the Reuters article

For decades, a daily dose of aspirin has been widely considered a way to protect healthy people from cardiovascular disease and even cancer. But a large international study finds that even at low doses, long-term use of aspirin may be harmful — without providing any benefit — for older people who have not already had a heart attack or stroke.

The new research reinforces the results of a study published in late August, which found that daily low-dose aspirin was too risky to be prescribed to patients at moderate risk of heart disease. In the August study and the new one, researchers found a significant risk of internal gastric bleeding caused by the medication, which thins the blood. Older patients experienced no health benefits from taking aspirin, according to the new report, published Sunday in the New England Journal of Medicine.

“We knew there would an increased risk of bleeding with aspirin, because there has always been," said study coauthor Dr. Anne Murray, a geriatrician and epidemiologist at the Hennepin Healthcare Research Institute and the University of Minnesota, Minneapolis. "But not only did it not decrease risk of disability or death, it did not decrease the risk of heart attack and stroke, and there was an increase in the rate of death."

Read / Watch the NBC News story

There's disappointing news for seniors: A new trial shows that taking daily low-dose aspirin doesn't prolong healthy, independent living in otherwise healthy people aged 70 and older.

Aspirin has long been recommended for middle-aged folks with a history of heart disease, to prevent future heart attacks or strokes.

Researchers had hoped that aspirin's specific effects might help folks ease gracefully into their old age.

"The thinking was the double action of blood thinning and anti-inflammation might decrease the risk of dementia and disability," explained senior researcher Dr. Anne Murray, director of the Berman Center for Outcomes and Clinical Research at Hennepin Healthcare in Minneapolis.

But a major new clinical trial has concluded that daily aspirin does not prolong disability-free survival in the elderly.

Read the story on HealthDay

Another clinical trial has added more evidence against the fairly common practice of prescribing aspirin to healthy older adults in order to prevent the onset of cardiovascular disease.

The clinical trial, which ran from 2010 to 2014 and included 19,114 individuals 70 years and older from the U.S. and Australia, found that a low daily dose of aspirin only marginally decreased a patient's risk of cardiovascular disease while significantly increasing the patient's risk of hemorrhage. Additionally, higher death rates were reported among those taking aspirin daily although the researchers are skeptical about how much weight to put on the finding since it's an unexpected outcome compared to similar studies.

"For a healthy person 70 and older who doesn't have an indication to be on aspirin, there really is no benefit to be on aspirin, in fact, the risks appear to outweigh the benefits in terms of increase bleeding risk and the potential for increased mortality risk," said Dr. Anne Murphy, co-principal investigator of the trial and director of the Berman Center for Outcomes and Clinical Research.

Read the Modern Healthcare article

Millions of healthy people who take aspirin to ward off illness in old age are unlikely to
benefit from the drug, a trial has found.

While a daily dose of the blood-thinning medicine can protect older people who have
previously experienced heart attacks, strokes and angina, researchers found the drug did
not extend the lifespan of healthy people over the age of 70.

Doctors in Australia and the US enrolled more than 19,000 healthy people, mostly aged
over 70, for the trial. Half the participants were asked to take 100mg of aspirin each day,
while the rest took a placebo pill.

Read The Guardian (UK) article

July

People addicted to prescription opioids or heroin are far more likely to have run-ins with the
law than those who don't use opioids, according to a new study published Friday in JAMA
Network Open.

"There have been reports that jails and prisons are bearing the brunt of the opioid epidemic,
but we didn't know nationally how many people who use opioids are involved in the criminal
justice system," says Tyler Winkelman, a clinician-investigator at Hennepin Healthcare in Minneapolis, and lead author of the study.

Read the NPR story

May

Providing integrated medical care and social support services led to increased use of
primary care among vulnerable adults who were enrolled in a Medicaid accountable
care organization (ACO), according to two studies published in Medical Care Research
and Review

One study used Medicaid claims data for about 90,000 enrollees to compare the use of
medical services by Hennepin Health (Hennepin County, MN) ACO enrollees to non-ACO
Medicaid enrollees in the same geographic area. 

The second study used interview data from 35 Hennepin Health members enrolled for two or more years during the study period.

People take a vaccine for the flu every year to avoid getting sick, but researchers across the country are working on a vaccine to help opioid addicts avoid overdosing.

"Ultimately, I think it can save lives. A vaccine like this could offer sort of long lasting protection," said senior investigator at the Minneapolis Medical Research Foundation (MMRF) Dr. Marco Pravetoni. Pravetoni and his team at MMRF have been working on a vaccine for the last 10 years, with their primary focus on the prescription painkiller oxycontin.

Read the CircaNews story

input search string and hit enter